Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Long-term epidemiologic longitudinal study on the effect of vaccines on public inoculation.

Matsuoka I, Matsuoka T, Matsuoka A, Shigemura T, Agematsu K, Koike K.

Turk J Pediatr. 2012 Jul-Aug;54(4):376-81.

2.

Characterizing vaccine-associated risks using cubic smoothing splines.

Brookhart MA, Walker AM, Lu Y, Polakowski L, Li J, Paeglow C, Puenpatom T, Izurieta H, Daniel GW.

Am J Epidemiol. 2012 Nov 15;176(10):949-57. doi: 10.1093/aje/kws158. Epub 2012 Oct 25.

3.

Management of chickenpox with frozen mother's milk.

Verd S, López E.

J Altern Complement Med. 2012 Aug;18(8):808-10. doi: 10.1089/acm.2011.0472. Epub 2012 Jul 30.

PMID:
22845343
4.

Herpes zoster in a partially vaccinated pediatric population in central Israel.

Stein M, Cohen R, Bromberg M, Tasher D, Shohat T, Somekh E.

Pediatr Infect Dis J. 2012 Sep;31(9):906-9. doi: 10.1097/INF.0b013e31825d33f9.

PMID:
22627868
5.

Gianotti-Crosti syndrome following childhood vaccinations.

Retrouvey M, Koch LH, Williams JV.

Pediatr Dermatol. 2013 Jan-Feb;30(1):137-8. doi: 10.1111/j.1525-1470.2011.01636.x. Epub 2011 Dec 6. Review.

PMID:
22141410
6.

Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina.

Fridman D, Monti A, Bonnet MC, Armoni J, Stamboulian D.

Hum Vaccin. 2011 Oct;7(10):1066-71. doi: 10.4161/hv.7.10.17816. Epub 2011 Oct 1.

7.

Vaccine-related varicella-zoster rash in a hospitalized immunocompetent patient.

Bernstein P, Furuya Y, Steinberg S, Scully B, Larussa P, Gershon AA.

Am J Infect Control. 2011 Apr;39(3):247-9. doi: 10.1016/j.ajic.2010.06.027. Epub 2011 Jan 26.

PMID:
21269735
8.

Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months.

Knuf M, Zepp F, Meyer CU, Habermehl P, Maurer L, Burow HM, Behre U, Janssens M, Willems P, Bisanz H, Vetter V, Schmidt-Ott R.

Eur J Pediatr. 2010 Aug;169(8):925-33. doi: 10.1007/s00431-010-1142-6. Epub 2010 Feb 11.

PMID:
20148263
9.

The predilection of chickenpox exanthema to influenza vaccine injection site.

Ben-Shoshan M, Lejtenyi C, Primeau MN.

Pediatr Dermatol. 2009 Jul-Aug;26(4):481-2. doi: 10.1111/j.1525-1470.2009.00963.x.

PMID:
19689535
10.

Varicella-zoster vaccine virus: evolution in action.

Cohen JI.

Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):7-8. Epub 2006 Dec 21. No abstract available.

11.

Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts.

Quinlivan ML, Gershon AA, Al Bassam MM, Steinberg SP, LaRussa P, Nichols RA, Breuer J.

Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):208-12. Epub 2006 Dec 20.

12.

Enhanced chickenpox exanthema in vaccine injection site.

Hentgen V, Cohen R, Siegrist CA.

Scand J Infect Dis. 2006;38(10):920-1.

PMID:
17008239
13.

A new combination vaccine for measles, mumps, rubella and varicella.

Zareba G.

Drugs Today (Barc). 2006 May;42(5):321-9. Review.

PMID:
16801995
14.

Varicella zoster in children attending day care centers.

Marcitelli R, Bricks LF.

Clinics (Sao Paulo). 2006 Apr;61(2):147-52. Epub 2006 Apr 25.

15.

Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age.

Heininger U, Desgrandchamps D, Schaad UB.

Vaccine. 2006 Apr 12;24(16):3258-60. Epub 2006 Jan 19.

PMID:
16459000
16.

An evaluation of single nucleotide polymorphisms used to differentiate vaccine and wild type strains of varicella-zoster virus.

Quinlivan M, Gershon AA, Steinberg SP, Breuer J.

J Med Virol. 2005 Jan;75(1):174-80.

PMID:
15543576
17.

Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus.

Quinlivan ML, Gershon AA, Steinberg SP, Breuer J.

J Infect Dis. 2004 Aug 15;190(4):793-6. Epub 2004 Jul 15.

18.

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.

Nolan T, McIntyre P, Roberton D, Descamps D.

Vaccine. 2002 Dec 13;21(3-4):281-9.

PMID:
12450703
19.

The postmarketing safety profile of varicella vaccine.

Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA.

Vaccine. 2000 Nov 22;19(7-8):916-23.

PMID:
11115716
20.

Viral strain identification in varicella vaccinees with disseminated rashes.

LaRussa P, Steinberg SP, Shapiro E, Vazquez M, Gershon AA.

Pediatr Infect Dis J. 2000 Nov;19(11):1037-9. Erratum in: Pediatr Infect Dis J 2001 Jan;20(1):33.

PMID:
11099082
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk